Korea Arlico Pharm. Co., Ltd

Quick facts

Phase 2 pipeline

• ALC-2203-1
• ALC-2203-2 · Inflammation
  ALC-2203-2 is a selective and potent agonist of the GPR84 receptor.
• ALC-2203-AC · Pain
  ALC-2203-AC is a selective and potent agonist of the kappa opioid receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Korea Arlico Pharm. Co., Ltd portfolio CI brief
• Korea Arlico Pharm. Co., Ltd pipeline updates RSS